We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
Cap. Flow
+$12.3M
Cap. Flow %
0.52%
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$32.6M
2
LLY icon
Eli Lilly
LLY
+$25.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
5
WELL.PRI
Welltower Inc.
WELL.PRI
+$11.7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$58.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.9M
3
ILMN icon
Illumina
ILMN
+$13.4M
4
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$12.5M
5
ALR
Alere Inc
ALR
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.12%
2 Real Estate 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
76
Exelixis
EXEL
$14.1B
$5.62M 0.24%
1,405,420
+381,543
+37% +$1.61M
RARE icon
77
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.6M 0.24%
88,400
– –
HR icon
78
Healthcare Realty
HR
$7.46B
$5.24M 0.22%
+178,033
New +$4.94M
ITCI
79
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.22M 0.22%
187,800
– –
EPZM
80
DELISTED
Epizyme, Inc
EPZM
$4.85M 0.21%
+400,000
New +$4.05M
PRGO icon
81
Perrigo
PRGO
$1.43B
$4.77M 0.2%
37,300
– –
MACK
82
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$4.77M 0.2%
72,434
-36,082
-33% -$1.88M
THC icon
83
Tenet Healthcare
THC
$21.8B
$4.76M 0.2%
164,500
– –
SAGE
84
DELISTED
Sage Therapeutics
SAGE
$4.71M 0.2%
146,800
+49,000
+50% +$1.72M
DVAX
85
DELISTED
Dynavax Technologies
DVAX
$4.64M 0.2%
240,950
-34,050
-12% -$688K
ELGX
86
DELISTED
Endologix Inc
ELGX
$4.61M 0.2%
55,100
– –
AGN.PRA
87
DELISTED
Allergan plc
AGN.PRA
$4.6M 0.2%
5,000
– –
TVTX icon
88
Travere Therapeutics
TVTX
$5.33B
$4.51M 0.19%
329,949
– –
KPTI icon
89
Karyopharm Therapeutics
KPTI
$159M
$4.46M 0.19%
33,355
– –
CTMX icon
90
CytomX Therapeutics
CTMX
$714M
$4.23M 0.18%
328,059
– –
HRTX icon
91
Heron Therapeutics
HRTX
$94.1M
$4.16M 0.18%
219,000
– –
BHC icon
92
Bausch Health
BHC
$2.25B
$4.16M 0.18%
+158,000
New +$11.7M
IPXL
93
DELISTED
Impax Laboratories, Inc.
IPXL
$3.98M 0.17%
124,335
-220,348
-64% -$7.75M
AXDX
94
DELISTED
Accelerate Diagnostics
AXDX
$3.8M 0.16%
26,463
– –
RCKT icon
95
Rocket Pharmaceuticals
RCKT
$351M
$3.61M 0.15%
121,848
+15,598
+15% +$468K
SGNT
96
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$3.49M 0.15%
286,650
– –
ONC
97
BeOne Medicines Ltd
ONC
$33.4B
$3.42M 0.15%
+116,707
New +$3.31M
CYTO
98
DELISTED
Altamira Therapeutics Ltd
CYTO
$3.04M 0.13%
10
-6
-38% -$2.14M
QURE icon
99
uniQure
QURE
$2.93B
$2.86M 0.12%
241,021
+65,521
+37% +$968K
NVRO
100
DELISTED
NEVRO CORP.
NVRO
$2.8M 0.12%
49,800
+24,800
+99% +$1.46M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
  • Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
  • Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
  • Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
  • Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.